Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Mifgyne
2. Mifegyne
3. Mifeprex
4. R 38486
5. R-38486
6. R38486
7. Ru 38486
8. Ru 486
9. Ru-38486
10. Ru-486
11. Ru38486
12. Ru486
13. Zk 98296
14. Zk-98296
15. Zk98296
1. 84371-65-3
2. Mifegyne
3. Mifeprex
4. Ru-486
5. Korlym
6. Ru486
7. Ru 486
8. Mifepriston
9. Corlux
10. Ru 38486
11. Ru-38486
12. Mls000069785
13. 320t6rnw1f
14. Vgx-410c
15. Chebi:50692
16. Vgx-410
17. Nsc-759862
18. Ncgc00025179-05
19. Smr000058481
20. Mifepristonum [latin]
21. Mifepristona [spanish]
22. Dsstox_cid_3322
23. C-1073
24. Dsstox_rid_76976
25. Dsstox_gsid_23322
26. (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)estra-4,9-dien-3-one
27. (8s,11r,13s,14s,17s)-11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-3-one
28. (8s,11r,13s,14s,17s)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
29. (8s,11r,13s,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
30. 11-(4-dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec Ahydro-cyclopenta[a]phenanthren-3-one
31. Mifepristona
32. Mifepristonum
33. (11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
34. Ru486 (tetramethyl-rhodamine Conjugated)
35. Mifepristone [usan:inn:ban]
36. Hsdb 6841
37. Sr-01000076011
38. R 38486
39. Brn 5779404
40. Unii-320t6rnw1f
41. Pictovir
42. Ru 486-6
43. Ccris 9332
44. 1nhz
45. 11beta-(p-(dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
46. Mifeprex (tn)
47. Pictovir (tm)
48. Prestwick_570
49. Cas-84371-65-3
50. Korlym (tn)
51. 2w8y
52. Mifepristone (mifeprex)
53. Opera_id_562
54. Mifepristone, >=98%
55. Prestwick0_000299
56. Prestwick1_000299
57. Prestwick2_000299
58. Prestwick3_000299
59. Spectrum5_002045
60. Mifepristone [mi]
61. Mifepristone [inn]
62. Mifepristone [jan]
63. Mifepristone [hsdb]
64. Mifepristone [usan]
65. 11beta-(4-(dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
66. 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
67. Mifepristone [vandf]
68. Bidd:pxr0123
69. Lopac0_000801
70. Schembl16087
71. Bspbio_000238
72. Mifepristone [mart.]
73. 11beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
74. 11beta-(4-(n,n-dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
75. Mls001074115
76. Mls001424271
77. (non-labelled)mifepristone-d3
78. Mifepristone [usp-rs]
79. Mifepristone [who-dd]
80. Spbio_002457
81. Ru-486; Mifepristone
82. Bpbio1_000262
83. Chembl438575
84. Gtpl2805
85. Mifepristone (jan/usan/inn)
86. Chembl1276308
87. Dtxsid5023322
88. Bdbm18627
89. Hms1568l20
90. Hms2052l05
91. Hms2090l22
92. Hms2095l20
93. Hms2230p21
94. Hms3262b03
95. Hms3412d17
96. Hms3649j08
97. Hms3676d17
98. Hms3712l20
99. Hms3884d12
100. Mifepristone [orange Book]
101. 11.beta.-(p-(dimethylamino)phenyl)-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
102. Act02598
103. Bcp02145
104. Zinc3831128
105. Tox21_110952
106. Tox21_301841
107. Tox21_500801
108. Bdbm50072024
109. Hsci1_000369
110. S2606
111. Vx-410
112. Akos015895416
113. Tox21_110952_1
114. Ccg-101164
115. Ci-1073
116. Cs-1435
117. Db00834
118. Lp00801
119. Nc00414
120. Nsc 759862
121. Sdccgsbi-0050778.p002
122. Mifepristone 1.0 Mg/ml In Acetonitrile
123. Ncgc00025179-06
124. Ncgc00025179-07
125. Ncgc00025179-08
126. Ncgc00025179-09
127. Ncgc00025179-12
128. Ncgc00025179-13
129. Ncgc00025179-23
130. Ncgc00179632-01
131. Ncgc00255152-01
132. Ncgc00261486-01
133. (11beta,17beta)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
134. As-13938
135. Cpd000058481
136. Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-, (11-beta,17-beta)-
137. Hy-13683
138. Ru486;c-1073
139. Eu-0100801
140. C07652
141. D00585
142. M 8046
143. 371m653
144. A840767
145. Q411240
146. Sr-01000721888
147. Q-201405
148. Sr-01000076011-1
149. Sr-01000076011-3
150. Sr-01000076011-5
151. Sr-01000076011-9
152. Sr-01000721888-4
153. Brd-k37270826-001-04-5
154. Brd-k37270826-001-31-8
155. Mifepristone, United States Pharmacopeia (usp) Reference Standard
156. (11?,17?)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
157. 11.beta.-[4-(dimethylamino)phenyl]-17.beta.-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
158. 11beta-(4-dimethylamino)phenyl-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
159. 11ss-[p-(dimethylamino)fenyl]-17ss-hydroxy- 17-(1-propynyl)estra-4,9-dien-3-on
160. (10s,11s,14s,15s,17r)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-1,6-dien-5-one
161. (10s,11s,14s,15s,17r)-17-[4-(dimethylamino)phenyl]-14-hydroxy-15-methyl-14-(prop-1-yn-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one
162. (11.beta.,17.beta.)-11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
163. (11r,13s,14s,17s)-11-(4-dimethylamino-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one
164. (8s,11r,13s,14s,17s)-11-[4-(dimethylamino)phenyl]-13-methyl-17-oxidanyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
165. 122742-25-0
166. 83203-42-3
167. Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propyn-1-yl)-, (11.beta.,17.beta.)-
168. Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11b,17b)-
| Molecular Weight | 429.6 g/mol |
|---|---|
| Molecular Formula | C29H35NO2 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 429.266779359 g/mol |
| Monoisotopic Mass | 429.266779359 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 921 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Korlym |
| PubMed Health | Mifepristone (By mouth) |
| Drug Classes | Antiglucocorticoid, Antiprogesterone |
| Drug Label | Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11-(4-dimethylaminophenyl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one. The chemical formula is C29H35NO2; the molecular wei... |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Corcept Therap |
| 2 of 4 | |
|---|---|
| Drug Name | Mifeprex |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg |
| Market Status | Prescription |
| Company | Danco Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Korlym |
| PubMed Health | Mifepristone (By mouth) |
| Drug Classes | Antiglucocorticoid, Antiprogesterone |
| Drug Label | Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11-(4-dimethylaminophenyl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one. The chemical formula is C29H35NO2; the molecular wei... |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 300mg |
| Market Status | Prescription |
| Company | Corcept Therap |
| 4 of 4 | |
|---|---|
| Drug Name | Mifeprex |
| Active Ingredient | Mifepristone |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 200mg |
| Market Status | Prescription |
| Company | Danco Labs |
Abortifacient Agents, Steroidal; Contraceptives, Oral, Synthetic; Contraceptives, Postcoital, Synthetic; Hormone Antagonists; Luteolytic Agents; Menstruation-Inducing Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Mifepristone is indicated in combination with misoprostol for the medical termination of intrauterine pregnancy of 49 days duration or less. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Confirmed or suspected ectopic pregnancy, undiagnosed adnexal mass, or IUD currently in place. Chronic adrenal failure or concurrent long-term corticosteroid therapy. Known hypersensitivity to mifepristone, misoprostol, or other prostaglandins. Hemorrhagic disorders, inherited porphyrias, or concurrent anticoagulant therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Vaginal bleeding that is heavier than associated with a normal menses occurs in almost all women receiving mifepristone and misoprostol. Based on clinical studies, bleeding or spotting should be expected for an average of 9-16 days. ... Excessive bleeding may require treatment with vasoconstrictors, saline infusions, and/or blood transfusions or curettage.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Severe vaginal bleeding may occur following spontaneous, surgical, or medical abortion (including following mifepristone administration). Prolonged heavy vaginal bleeding (i.e. soaking through 2 thick full-size sanitary pads per hour for 2 consecutive hours) may be a sign of incomplete abortion or other complications, and prompt medical or surgical intervention maybe required to prevent the development of hypovolemic shock. Patients should be advised to seek immediate medical attention if prolonged heavy vaginal bleeding or syncope occurs following mifepristone administration.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
Serious bacterial infections (including very rare cases of fatal septic shock) have been reported following mifepristone administration; a causal relationship to the mifepristone-misoprostol regimen has not been established. Clinicians should consider the possibility of infection if sustained fever (temperature of 38 degrees C or higher persisting for more than 4 hours), severe abdominal pain, or pelvic tenderness occurs within several days of medical abortion. Atypical presentations of serious infection and sepsis (i.e., presence of significant leukocytosis, tachycardia, or hemoconcentration without fever, severe abdominal pain, pelvic tenderness) may also occur.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148
For more Drug Warnings (Complete) data for MIFEPRISTONE (14 total), please visit the HSDB record page.
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
FDA Label
Treatment of endometriosis
Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin
Treatment of leiomyoma of uterus
Mifepristone is a synthetic steroid with antiprogestational effects indicated for the medical termination of intrauterine pregnancy through 49 days' pregnancy. Doses of 1 mg/kg or greater of mifepristone have been shown to antagonize the endometrial and myometrial effects of progesterone in women. During pregnancy, the compound sensitizes the myometrium to the contraction-inducing activity of prostaglandins. Mifepristone also exhibits antiglucocorticoid and weak antiandrogenic activity. The activity of the glucocorticoid dexamethasone in rats was inhibited following doses of 10 to 25 mg/kg of mifepristone. Doses of 4.5 mg/kg or greater in human beings resulted in a compensatory elevation of adrenocorticotropic hormone (ACTH) and cortisol.
Contraceptives, Oral, Synthetic
Oral contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Oral, Synthetic.)
Luteolytic Agents
Chemical compounds that cause LUTEOLYSIS or degeneration of the CORPUS LUTEUM. (See all compounds classified as Luteolytic Agents.)
Contraceptives, Postcoital, Synthetic
Postcoital contraceptives which owe their effectiveness to synthetic preparations. (See all compounds classified as Contraceptives, Postcoital, Synthetic.)
Abortifacient Agents, Steroidal
Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)
Menstruation-Inducing Agents
Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhea is a secondary result. (From Dorland, 27th ed) (See all compounds classified as Menstruation-Inducing Agents.)
Hormone Antagonists
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)
G03XB01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03X - Other sex hormones and modulators of the genital system
G03XB - Progesterone receptor modulators
G03XB01 - Mifepristone
Absorption
The absolute bioavailability of a 20 mg oral dose is 69%
Route of Elimination
Fecal: 83%; Renal: 9%.
The absolute bioavailability of oral mifepristone is 69%.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Protein binding: Very high (98%); predominantly to albumin and alpha1- acid glycoprotein.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Time to peak concentration: 90 minutes after a 600 mg oral dose.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Peak plasma concentration: 1.98 mg/L following a single 600 mg oral dose.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Fecal; 83% of a 600 mg dose over 11 days. Renal; 9% of a 600 mg dose over 11 days.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Hepatic. Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from the loss of two methyl groups from position 11 beta; and RU 42 698, which results from terminal hydroxylation of the 17–propynyl chain.
Hepatic, by Cytochrome P450 3A4 isoenzyme to the N-monodemethylated metabolite (RU 42 633); RU 42 698, which results from terminal hydroxylation of the 17-propynyl chain.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
Mifepristone has known human metabolites that include 17alpha-hydroxymifepristone and Monodemethylated mifepristone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
18 hours
Terminal: 18 hours; begins slowly and becomes more rapid with time.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results. In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
Mifepristone competitively inhibits the actions of progesterone at progesterone-receptor sites, resulting in termination of pregnancy.The combination of mifepristone and misoprostol causes expulsion of the products of conception through decidual necrosis, myometrial contractions, and cervical softening.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 1971
When administered in the early stages of pregnancy, mifepristone causes decidual breakdown by blockade of uterine progesterone receptors. This leads to detachment of the blastocyte, which decreases hCG production. This in turn causes a decrease in progesterone secretion from the corpus luteum, which further accentuates decidual breakdown. Decreased endogenous progesterone coupled with blockade of progesterone receptors in the uterus increases prostaglandin levels and sensitizes the myometrium to the contractile actions of prostaglandins.
Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1622
In addition, mifepristone promotes uterine contractions and softening of the cervix and sensitizes the myometrium to effects of prostaglandins (e.g., misoprostol) that stimulate uterine contraction and expulsion of the products of conception. In the absence of progesterone, mifepristone acts as a partial progestin agonist. At dosages higher than those used for termination of pregnancy, mifepristone also exhibits antiglucocorticoid activity. The drug also has been shown to have weak antiandrogenic activity.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3148

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
CAS Number : 39416-48-3
End Use API : Mifepristone
About The Company : NINGBO INNO PHARMCHEM CO.,LTD. develop, pilot and commercial produce organic chemicals, pharmaceutical intermediates and nutraceuticals. We also offer custom sy...

19-nor-5(10)-androstene-3,17-dione
CAS Number : 3962-66-1
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...

3-ethylene dioxy-17-oxo-13ß-methyl-estra-5(10),9(...
CAS Number : 24916-90-3
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...

5a,10a-epoxy-3,3-ethylenedioxy-17a-propynyl-estra-...
CAS Number : 84371-57-3
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...

3-(1,2-ethanediyl-bosoxy)-11a-(4-(n,n- dimethylami...
CAS Number : 84371-64-2
End Use API : Mifepristone
About The Company : With the high technology and excellent services, Xianju pharma earned a top worldwide reputation for quality in pharmaceutical industry. Xianju pharma has dedic...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : KORLYM
Dosage Form : TABLET;ORAL
Dosage Strength : 300MG
Approval Date : 2012-02-17
Application Number : 202107
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : MIFEPREX
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2000-09-28
Application Number : 20687
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : MIFEPRISTONE
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2019-04-11
Application Number : 91178
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : MIFEPRISTONE
Dosage Form : TABLET;ORAL
Dosage Strength : 300MG
Approval Date : 2020-08-03
Application Number : 211436
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Brand Name : MIFEPRISTONE
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2025-09-30
Application Number : 216616
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 10-09-2021
Application Number : 28106631821
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 200mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 600MG
Packaging :
Approval Date : 11-06-2019
Application Number : 84219
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 04-09-1992
Application Number : 1.99E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Mifepriston Linepharma
Dosage Form : Tablet
Dosage Strength : 200MG
Packaging :
Approval Date : 13-11-2013
Application Number : 77617
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 14/07/1999
Application Number : 55205
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Mifegyne
Dosage Form : Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 12-06-2020
Application Number : 28106414820
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Moldova
Brand Name : Medabon
Dosage Form : Vaginal Tablets
Dosage Strength : 200mg; 0.2mg
Packaging :
Approval Date : 09-04-2020
Application Number :
Regulatory Info :
Registration Country : Moldova

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Meda Subscriber
Dosage Form : Vaginal Tablet
Dosage Strength : 200mg;(4x0.2mg)
Packaging :
Approval Date : 02-08-2012
Application Number : 2.01E+13
Regulatory Info : Deregistered
Registration Country : Sweden

Regulatory Info :
Registration Country : Italy
Brand Name : Mifegyne
Dosage Form : Mifepristone 200Mg 1 Combined Oral Use
Dosage Strength : 1 CPR 200 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MIFEGYMISO
Dosage Form : TABLET
Dosage Strength : 200MG
Packaging : 1 MIFEPRISTONE AND 4 MISOPROSTOL PER PACK
Approval Date :
Application Number : 2444038
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Australia
Brand Name : MS-2 Step
Dosage Form : tablet
Dosage Strength : 200 mg
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Mediprist 200 mg
Dosage Form : TAB
Dosage Strength : 200mg
Packaging : 1X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Mifegyne
Dosage Form : TAB
Dosage Strength : 200mg
Packaging : 3X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : MEDABON CO
Dosage Form : KIT
Dosage Strength : 200mg
Packaging : 5X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.
Pharmacopoeia Ref : NA
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Coating Systems & Additives
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Emulsion, Tablet
Grade : Oral, Ophthalmic
Category : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Brand Name : Hydroxypropyl Methyl Cellulose
Application : Disintegrants & Superdisintegrants, Emulsifying Agents, Film Formers & Plasticizers, Thickeners and Stabilizers
Excipient Details : Hydroxypropyl Methyl Cellulose is used as a film-former, disintegrant, thickener, and emulsifier in tablets, emulsions, and ophthalmic formulations.
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Chewable & Orodispersible Aids, Coating Systems & Additives
Application : Chewable & Orodispersible Aids, Coating Systems & Additives
Excipient Details : Instacoat CFC is an HPMC & xylitol-based high-speed optimized chewable and crunchy film coating material.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Oral
Category : Coating Systems & Additives, Fillers, Diluents & Binders, Granulation
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Enteric Coatings
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Immediate Release
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Not Available
Category : Coating Systems & Additives, Controlled & Modified Release
Application : Coating Systems & Additives, Controlled & Modified Release
Excipient Details : Enteric Coatings
Application : Empty Capsules
Excipient Details : Quali-V®-I is the first plant-based capsule that responds to the particular functional properties required for use in dry powder inhaler (DPI) devices.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Application : Empty Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 00el - 4
Ingredient(s) : Gelatin Excipient
Grade : Not Available
Category : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Application : API Stability Enhancers, Coating Systems & Additives, Controlled & Modified Release, Direct Compression, Granulation, Rheology Modifiers, Vegetarian Capsules
Excipient Details : Controlled Release, Direct Compression,Wet Granulation,Tablet Coating, Liquid Solutions and Suspensions
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Capsule
Grade : Oral and Inhalation
Category : API Stability Enhancers, Vegetarian Capsules
Application : API Stability Enhancers, Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : "Water content – less than 9%, can be customized; Size # 00el -...
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Application : Controlled & Modified Release, Vegetarian Capsules
Pharmacopoeia Ref : Complies with relevant Europea...
Technical Specs : Water content – less than 6%; Size #0
Ingredient(s) : Hypromellose Acetate Succinate
Dosage Form : Capsule
Grade : Oral
Category : API Stability Enhancers, Taste Masking, Vegetarian Capsules
Application : API Stability Enhancers, Taste Masking, Vegetarian Capsules
Pharmacopoeia Ref : Certified Vegan, Non-GMO, Vege...
Technical Specs : Size # 0-1
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
13
PharmaCompass offers a list of Mifepristone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Mifepristone manufacturer or Mifepristone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Mifepristone manufacturer or Mifepristone supplier.
PharmaCompass also assists you with knowing the Mifepristone API Price utilized in the formulation of products. Mifepristone API Price is not always fixed or binding as the Mifepristone Price is obtained through a variety of data sources. The Mifepristone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex, including repackagers and relabelers. The FDA regulates RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex supplier is an individual or a company that provides RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex active pharmaceutical ingredient (API) or RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex finished formulations upon request. The RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers may include RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex API manufacturers, exporters, distributors and traders.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex DMF (Drug Master File) is a document detailing the whole manufacturing process of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex active pharmaceutical ingredient (API) in detail. Different forms of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex DMFs exist exist since differing nations have different regulations, such as RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex DMF submitted to regulatory agencies in the US is known as a USDMF. RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex USDMF includes data on RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex Drug Master File in Japan (RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex JDMF) empowers RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex JDMF during the approval evaluation for pharmaceutical products. At the time of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers with JDMF on PharmaCompass.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex written confirmation (RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex WC) is an official document issued by a regulatory agency to a RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex manufacturer, verifying that the manufacturing facility of a RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex APIs or RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex finished pharmaceutical products to another nation, regulatory agencies frequently require a RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex WC (written confirmation) as part of the regulatory process.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex suppliers with NDC on PharmaCompass.
RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex GMP manufacturer or RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex GMP API supplier for your needs.
A RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex CoA (Certificate of Analysis) is a formal document that attests to RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex's compliance with RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex specifications and serves as a tool for batch-level quality control.
RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex CoA mostly includes findings from lab analyses of a specific batch. For each RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex may be tested according to a variety of international standards, such as European Pharmacopoeia (RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex EP), RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RU-486;RU-38486;Mifegyne;Mifeprex;Mifeprex USP).